Transcatheter Aortic Valve Replacement: An Update in Bicuspid Aortic Valve Disease
Published: 13 July 2020
-
Views:
39
-
Likes:
7
-
Views:
39
-
Likes:
7
-
11m 17s
-
14m 45sPart 4 Discussion and Q&As
Overview
Considering the promising outcomes and FDA approval in low-risk patients, the number of transcatheter aortic valve replacement (TAVR) procedures is expected to increase significantly in the coming years. According to the most recent data presented at the American College of Cardiology (ACC) 2020, bicuspid aortic valve disease (BAV) patients who undergo TAVR procedures had a low risk of death or disabling stroke and high rate of success with a newer self-expanding artificial valve (Evolut supra-annular self-expanding valves, Medtronic). Further, BAV patients reported to have a similar rate of death compared with tricuspid aortic valve disease patients following TAVR using the balloon-expandable valve (Edwards Sapien 3, Edwards Lifesciences).
Improving efficacy and reduction in operator variability is essential to ensure the adoption of TAVR for BAV patients. In particular, the BAV morphologies will remain challenging and require accurate pre- and peri-procedural work up.
This programme has therefore been designed for an audience of cardiologists and surgeons to build their understanding of bicuspid valve disease and classifications, clinical trial data supporting TAVR in low-risk bicuspid patients, implant techniques, and device considerations for bicuspid patients.
Learning Objectives
- Describe the Latest Data in Bicuspid Valve Disease and Understand the Classifications
- Critically Evaluate Clinical Trial Data in TAVR in Low-Risk Bicuspid Patients
- Review Implant Techniques and Device Considerations for Bicuspid Patients
More from this programme
Part 1
Programme Introduction and TAVR in Low Risk Bicuspid Patients: Critical Review of the Clinical Evidence
Part 2
Implant Techniques and Device Selections for Bicuspid Patients
Part 3
TAVR in Bicuspid Patients: Case Reviews
Part 4
Discussion and Q&As
| 1 session | |
| Discussion and Q&As | Watch now |
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Dr Nicolas M Van Mieghem obtained his medical degree and cardiology degree at the Catholic University of Leuven, Belgium. After subsequent fellowships in interventional cardiology in Ziekenhuis Oost-Limburg Genk, Belgium, Lenox Hill Hospital, New York, US and Erasmus Medical Center, Rotterdam, the Netherlands, he joined the department of interventional cardiology at the Thoraxcenter, Erasmus Medical Center, as a senior staff member in February 2010.
He is involved in the percutaneous coronary interventions and structural heart program. He obtained the degree of PhD based upon his research in transcatheter valve therapies. So far he has published and co-authored approximately 130 scientific papers in peer-reviewed journals.
Dr Van Mieghem is principle investigator and steering committee member in multiple ongoing international trials evaluating various coronary and transcatheter valve technologies. He is a Fellow of the European Society of Cardiology and is currently…
